SCM
BLRX

Silverarc Capital Management’s BioLineRX BLRX Stock Holding History

Silverarc Capital Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,000
Closed -$558K – 102
2021
Q1 		$558K Buy
+5,000
New +$601K 0.3% 70

Other funds holding BLRX

PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
GPFA
Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Silverarc Capital Management's BLRX Position: Q2 2021 in Review

Silverarc Capital Management sold out of BioLineRX (BLRX) in Q2 2021, closing a stake of 5,000 shares — an estimated $558K sold.

Silverarc Capital Management first reported a position in BLRX in Q1 2021 and held it in 1 quarter. The position peaked at $558K in Q1 2021. 28 funds tracked by Wall St. Rank hold BLRX as of Q2 2021.

  • Silverarc Capital Management reported no remaining BioLineRX position as of Q2 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 5,000 BioLineRX shares in Q2 2021, an estimated $558K.
  • Silverarc Capital Management first reported a position in BioLineRX in Q1 2021 and held it in 1 quarter.
  • Silverarc Capital Management's BioLineRX position peaked at $558K in Q1 2021.
  • 28 funds tracked by Wall St. Rank held BioLineRX as of Q2 2021.

Based on Silverarc Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.